Use of MAGE A3-protein D fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer

Details for Australian Patent Application No. 2008204526 (hide)

Owner GlaxoSmithKline Biologicals sa

Inventors Gerard, Catherine Marie Ghislaine; Louahed, Jamila; Lehmann, Frederic Francois Eugene; Brichard, Vincent

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008204526

PCT Pub. Number WO2008/084040

Priority 0700284.3 08.01.07 GB

Filing date 8 January 2008

Wipo publication date 17 July 2008

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

16 July 2009 PCT application entered the National Phase

  PCT publication WO2008/084040 Priority application(s): WO2008/084040

22 December 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008204530-Urea glucokinase activators

2008204523-Emitter location